Predicting which glioblastoma patients may benefit from drug treatment
Monday, June 29, 2015 - 15:30
in Health & Medicine
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers who conducted one of those clinical trials, believe they know why dasatinib failed — and what to do about it.